Amgen's Repatha India Trial Waiver Plan Trips Up
Executive Summary
Amgen's PCSK9 inhibitor Repatha, already constrained by payor pushbacks on prices in the West and awaiting outcomes data, now appears to be facing a challenge in India. A key Indian expert panel has turned down Amgen's request for a trial waiver for evolocumab, a move that could hold up launch plans with partner Dr Reddy's.